Hetero Drugs
HETERO 由Dr. B. P. S. Reddy 與技術專家隊創立于1993年,并迅速在印度制藥行業躋身前十位,是一家綜合性的制藥公司,具有完善的研發、生產和銷售體系,從事中間體的開發和生產,原料藥(API)和成品制劑,擁有全球認可的生產設施,在國際市場上占有一席之地。
Hetero在海德拉巴以及周邊地區有9個原料藥設施,迄今為止有200多種原料藥在市場上供應,是抗逆轉錄病毒藥(包括原料藥和成品)的最大生產商,是印度市場上最大的成品制劑的合同生產商,現已生產了超過250項產品,包括360億片劑及5億膠囊,不同程度上占據著印度本土市場,在印度眾制藥公司中屬于成品制劑的名牌生產商。
Hetero擁有強大的研發平臺------40個實驗室和350位科學家的世界級的研究中心,在Hetero研究基地有不止200種先進的原料藥先進的工序,平均每年有15種原料藥和40種中間體從研發中心轉移到生產再供應于全球不同的市場。
Hetero共有員工7000人(其中包括研發人員350位,化學家和工程師3500位)負責承辦原料藥、中間體和成品制劑的OEM生產,提供完善的原料藥和成品制劑。在2010年全球銷售額為8億美金,中國地區采購額為6700萬美金。
Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.
Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization. Hetero is a leading international supplier with a rich portfolio of over 200 products from wide range of therapeutic categories both in active pharmaceutical ingredients and finished dosages.
Hetero’s manufacturing facilities are cGMP compliant meeting global standards in terms of infrastructure and systems. Majority of them are approved by the various regulatory authorities of USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines & health care products, ANVISA-Brazil, IDA-Netherlands etc.,
With full-fledged marketing capabilities, the company has been able to market its products in over 138 countries across the globe.